DaVita (NYSE:DVA) Releases FY 2026 Earnings Guidance
by Doug Wharley · The Cerbat GemDaVita (NYSE:DVA – Get Free Report) updated its FY 2026 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of 13.600-15.00 for the period, compared to the consensus estimate of 12.800. The company issued revenue guidance of -.
Analyst Ratings Changes
A number of equities analysts recently weighed in on the company. Wall Street Zen lowered DaVita from a “buy” rating to a “hold” rating in a research report on Saturday, October 11th. Truist Financial decreased their target price on shares of DaVita from $140.00 to $128.00 and set a “hold” rating for the company in a report on Monday, January 5th. Zacks Research raised shares of DaVita from a “strong sell” rating to a “hold” rating in a research report on Friday, November 28th. Barclays reduced their price target on shares of DaVita from $149.00 to $143.00 and set an “equal weight” rating for the company in a research report on Thursday, October 30th. Finally, UBS Group reaffirmed a “buy” rating on shares of DaVita in a research note on Monday, December 15th. One research analyst has rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, DaVita currently has a consensus rating of “Hold” and a consensus price target of $145.60.
Read Our Latest Research Report on DVA
DaVita Price Performance
DVA traded up $1.87 during trading on Monday, reaching $111.21. 2,417,774 shares of the stock traded hands, compared to its average volume of 995,500. The stock’s 50-day simple moving average is $113.59 and its two-hundred day simple moving average is $125.09. DaVita has a fifty-two week low of $101.00 and a fifty-two week high of $178.47. The stock has a market cap of $7.85 billion, a price-to-earnings ratio of 11.45, a price-to-earnings-growth ratio of 0.67 and a beta of 0.99.
DaVita (NYSE:DVA – Get Free Report) last issued its earnings results on Monday, February 2nd. The company reported $3.40 earnings per share for the quarter, topping the consensus estimate of $3.34 by $0.06. The company had revenue of $3.62 billion for the quarter, compared to analyst estimates of $3.51 billion. DaVita had a negative return on equity of 13,370.89% and a net margin of 5.80%.DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. Research analysts anticipate that DaVita will post 10.76 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently modified their holdings of the business. NewEdge Advisors LLC lifted its stake in shares of DaVita by 20.8% in the 1st quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock valued at $78,000 after purchasing an additional 88 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in DaVita by 19.1% during the first quarter. Goldman Sachs Group Inc. now owns 179,140 shares of the company’s stock valued at $27,403,000 after buying an additional 28,739 shares in the last quarter. Cerity Partners LLC raised its holdings in DaVita by 7.0% during the second quarter. Cerity Partners LLC now owns 2,638 shares of the company’s stock valued at $376,000 after buying an additional 172 shares in the last quarter. Bank of Nova Scotia lifted its position in shares of DaVita by 3.8% in the second quarter. Bank of Nova Scotia now owns 4,813 shares of the company’s stock worth $686,000 after buying an additional 176 shares during the last quarter. Finally, Natixis boosted its stake in shares of DaVita by 80.9% during the 2nd quarter. Natixis now owns 7,297 shares of the company’s stock worth $1,039,000 after acquiring an additional 3,264 shares in the last quarter. Institutional investors own 90.12% of the company’s stock.
About DaVita
DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.
Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.